⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ODTX News
Odyssey Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
ODTX
Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026
globenewswire.com
ODTX
Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026
globenewswire.com
ODTX
Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026
globenewswire.com
ODTX
Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum
globenewswire.com
ODTX
Form 8-K
sec.gov
ODTX
Odyssey Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com
ODTX
Form 8-K
sec.gov
ODTX
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
ODTX
Form 8-K
sec.gov
ODTX